Direkt zum Inhalt
Merck
  • MicroRNA-92a inhibition attenuates hypoxia/reoxygenation-induced myocardiocyte apoptosis by targeting Smad7.

MicroRNA-92a inhibition attenuates hypoxia/reoxygenation-induced myocardiocyte apoptosis by targeting Smad7.

PloS one (2014-06-19)
Busheng Zhang, Mi Zhou, Canbo Li, Jingxin Zhou, Haiqing Li, Dan Zhu, Zhe Wang, Anqing Chen, Qiang Zhao
ZUSAMMENFASSUNG

MicroRNAs (miRNAs) regulate a lot of physiological and pathological processes, including myocardial ischemia/reperfusion. Recent studies reported that knockdown of miR-92a could attenuate ischemia/reperfusion-induced myocardial injury. In the present study, we examined the potential anti-apoptotic effects of miR-92a in a rat myocardiocyte cell line, and the possible role of Smad7 in such actions. In a preliminary bioinformatic analysis, we identified SMAD family member 7 (Smad7) as a potential target for miR-92a. A luciferase reporter assay indeed demonstrated that miR-92a could inhibit Smad7 expression. Myocardial ischemia/reperfusion was simulated in rat H9c2 cells with 24-h hypoxia followed by 12-h reoxygenation. Prior to hypoxia/reoxygenation, cells were transfected by miR-92a inhibitor. In some experiments, cells were co-transfected with siRNA-Smad7. The miR-92a inhibitor dramatically reduced the release of lactate dehydrogenase and malonaldehyde, and attenuated cardiomyocyte apoptosis. The miR-92a inhibitor increased SMAD7 protein level and decreased nuclear NF-κB p65 protein. Effects of the miR-92a inhibitor were attenuated by co-transfection with siRNA-Smad7. Inhibiting miR-92a can attenuate myocardiocyte apoptosis induced by hypoxia/reoxygenation by targeting Smad7.

MATERIALIEN
Produktnummer
Marke
Produktbeschreibung

Sigma-Aldrich
Propidiumjodid, ≥94.0% (HPLC)
Sigma-Aldrich
Propidiumjodid -Lösung
Sigma-Aldrich
Propidiumjodid, ≥94% (HPLC)
Sigma-Aldrich
MISSION® esiRNA, targeting human SMAD7